Inhibitory influence of chromogranin A N-terminal fragment (vasostatin-1) on the spontaneous contractions of rat proximal colon.
Very little is known about the role played by CGA and its fragments in the gastrointestinal physiology. We have studied the role of CGA N-terminal fragments in the regulation of intestinal smooth muscle contractility by measuring the influence of recombinant CGA 1-78 (VS-1) and synthetic CGA 7-57 peptides on the spontaneous mechanical activity of rat proximal colon in vitro. The mechanical activity was recorded as changes in the intraluminal pressure. VS-1 (0.1-30 nM) and CGA 7-57 (10-300 nM) produced concentration-dependent inhibitory effects, characterized by a progressive decrease in the mean amplitude of circular muscle spontaneous contractions, without affecting the resting tone. The response to VS-1 was antagonised by anti-CGA monoclonal antibodies (mAb5A8, B4E11, 7D1 or 4D5) but not by an irrelevant antibody, indicating that the effect was specific. The inhibitory responses to VS-1 and to CGA 7-57 were significantly reduced by pre-treatment of the preparations with N(omega)-nitro-l-arginine methyl ester (l-NAME) (300 microM), 1H-(1,2,4) oxadiazolo-(4,3-a) quinoxalin-1-one (ODQ) (10 microM), apamin (0.1 microM) or tetrodotoxin (TTX) (1 microM). The results suggest that VS-1 plays an inhibitory modulatory role on spontaneous contractions rat colon circular muscle, through mechanisms involving in part neural release of nitric oxide.
Amato
Antonella
A
Dipartimento di Biologia cellulare e dello Sviluppo, Laboratorio di Fisiologia generale Università di Palermo, Viale delle Scienze, 90128 Palermo, Italy.
Corti
Angelo
A
Serio
Rosa
R
Mulè
Flavia
F
D000818:Animals; D001030:Apamin / Q000494:pharmacology; D037282:Calreticulin / Q000494:pharmacology; D053379:Chromogranin A; D002864:Chromogranins / Q000737:chemistry* / Q000494:pharmacology; D003106:Colon / Q000187:drug effects / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D041981:Gastrointestinal Tract / Q000378:metabolism; D009119:Muscle Contraction / Q000187:drug effects*; D009130:Muscle, Smooth / Q000187:drug effects; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000378:metabolism; D010069:Oxadiazoles / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D010455:Peptides / Q000737:chemistry; D011312:Pressure; D017434:Protein Structure, Tertiary; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000737:chemistry; D013779:Tetrodotoxin / Q000494:pharmacology; D013997:Time Factors
C095284:1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one; D037282:Calreticulin; D053379:Chromogranin A; D002864:Chromogranins; D004791:Enzyme Inhibitors; D010069:Oxadiazoles; D010446:Peptide Fragments; D010455:Peptides; D011810:Quinoxalines; D011994:Recombinant Proteins; C505867:chromogranin A (1-78); C499788:chromogranin A (7-57); C506153:chromogranin A, rat; C121986:vasostatin; D001030:Apamin; D009569:Nitric Oxide; D013779:Tetrodotoxin; D019331:NG-Nitroarginine Methyl Ester